AR063376A1 - Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento - Google Patents

Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento

Info

Publication number
AR063376A1
AR063376A1 ARP070104708A ARP070104708A AR063376A1 AR 063376 A1 AR063376 A1 AR 063376A1 AR P070104708 A ARP070104708 A AR P070104708A AR P070104708 A ARP070104708 A AR P070104708A AR 063376 A1 AR063376 A1 AR 063376A1
Authority
AR
Argentina
Prior art keywords
metabolites
hydroxy
derivatives
demetilvenlafaxine
oxide
Prior art date
Application number
ARP070104708A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR063376A1 publication Critical patent/AR063376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente proporciona compuestos aislados caracterizados como metabolitos o derivados de desmetilvenlafaxina incluyendo metabolitos de hidroxi-DV, metabolitos de hidroxi-DV-glucuronido, metabolitos de N-oxido-DV, y metabolitos de bencil-hidroxi- DV. La presente incluye composiciones farmacéuticas que comprenden cualquiera de los metabolitos o derivados de esta solicitud en combinacion con un portador o excipiente farmacéuticamente aceptable. También se incluye un método de tratamiento de al menos un trastorno del sistema nervioso central en un mamífero, que comprende suministrar a un mamífero que necesite del mismo, una cantidad efectiva de los compuestos de la presente.
ARP070104708A 2006-10-25 2007-10-24 Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento AR063376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85406306P 2006-10-25 2006-10-25

Publications (1)

Publication Number Publication Date
AR063376A1 true AR063376A1 (es) 2009-01-28

Family

ID=39103391

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104708A AR063376A1 (es) 2006-10-25 2007-10-24 Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento

Country Status (12)

Country Link
US (1) US20080261895A1 (es)
EP (1) EP2086922A2 (es)
JP (1) JP2010507667A (es)
CN (1) CN101528667A (es)
AR (1) AR063376A1 (es)
CA (1) CA2666350A1 (es)
CL (1) CL2007003067A1 (es)
MX (1) MX2009004247A (es)
PE (1) PE20081138A1 (es)
RU (1) RU2009112105A (es)
TW (1) TW200826925A (es)
WO (1) WO2008051558A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696383B2 (en) * 2007-06-26 2010-04-13 Solvay Pharmaceuticals B.V. N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs
CN109761826B (zh) * 2019-01-17 2022-02-25 烟台大学 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
EP1153603B1 (en) * 1993-06-28 2006-10-18 Wyeth New treatments using phenethylamine derivatives
HUP0303128A3 (en) * 2001-02-12 2008-03-28 Wyeth Corp Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it

Also Published As

Publication number Publication date
US20080261895A1 (en) 2008-10-23
JP2010507667A (ja) 2010-03-11
PE20081138A1 (es) 2008-09-18
WO2008051558A3 (en) 2008-08-14
CL2007003067A1 (es) 2008-04-11
EP2086922A2 (en) 2009-08-12
CN101528667A (zh) 2009-09-09
TW200826925A (en) 2008-07-01
WO2008051558A2 (en) 2008-05-02
RU2009112105A (ru) 2010-11-27
MX2009004247A (es) 2009-05-14
CA2666350A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CL2007002356A1 (es) Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros.
CR10427A (es) Quinazolinas para la inhibicion de pdk1
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
CR11731A (es) Composiciones y procedimientos para su preparación y uso
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
CY1114363T1 (el) Ανθελμινθικος συνδυασμος
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR20110103A (es) Heteroarilos sustituidos
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
MX2010002316A (es) Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
GT201200193A (es) Derivados de aril triazol heteroarmoaticos como inhibidores de enzima pde10a
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
CR11290A (es) Derivados de ciclopropilamida
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
AR071309A1 (es) Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten

Legal Events

Date Code Title Description
FB Suspension of granting procedure